Amivantamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted amivantamab, while AOTMIT (Poland) did not recommend it.
The record spans 4.6 years, opening at AWMSG (Wales) on 9 Dec 2021 and running to 9 Jul 2026.
NYE METODER (Norway) changed its position: not recommended on 18 Jun 2023, recommended by 14 Jun 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for amivantamab, 2 submissions were never made — an outcome set by the company rather than the assessor.
The file is active: 41 of 47 records date from 2023 or later.
The programme is broad: 11 distinct indication wordings are recorded for amivantamab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 47 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess amivantamab, on 9 Dec 2021; ZIN (Netherlands) did not open a file until 9 Jul 2026 — a wide spread of 4.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 20 of 47 dated records fall in 2025 alone.
12 of the 13 agencies here assessed amivantamab more than once, CIPM (Spain) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
amivantamab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for amivantamab reads 18 recommended, 15 not recommended, 5 no benefit and 3 deferred to NICE, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Non-small cell lung cancer (NSCLC) | Recommended | source |
| HIRA (South Korea) | 7 May 2026 | 백금 기반 화학요법 치료 중 또는 치료 이후에 질병이 진행된 표피성장인자수용체 엑손 20 삽입 변이가 있는 국소 진행성 또는 전이성 비소세포폐암 성인 환자에서의 단독요법 | deferred for re-review | source |
| NICE (England) | 21 Jan 2026 | NICE TA1122 | published appraisal | source |
| SMC (Scotland) | 10 Mar 2025 | In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21… | not recommended | source |
| NYE METODER (Norway) | 18 Jun 2023 | Behandling av voksne pasienter med metastatisk ikke-småcellet lungekreft (NSCLC) med EGFR ekson 20 innsettingsmutasjon e… | not introduced | source |
42 further decisions for amivantamab, across 13 agencies, are not shown here. They include the most recent record on file, 9 Jul 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 32 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 47 decisions for amivantamab from 13 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.